Exploration of molecular mechanisms and targeted therapies for KRAS mutations in pancreatic ductal adenocarcinoma
10.3781/j.issn.1000-7431.2024.2402-0083
- VernacularTitle:胰腺导管腺癌KRAS突变的分子机制与靶向疗法探索
- Author:
Yongzhi CHEN
1
;
Yanjing LI
;
Yingbin LIU
Author Information
1. 上海交通大学医学院附属仁济医院胆胰外科,上海 200127
- Publication Type:Journal Article
- Keywords:
Pancreatic ductal adenocarcinoma;
KRAS gene;
Targeted drugs
- From:
Tumor
2024;44(3):278-289
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic ductal adenocarcinoma is a highly malignant gastrointestinal tumour with increasing incidence,and KRAS(KRAS Proto-Oncogene,GTPase)gene mutation is the main driver of its development.Pancreatic ductal adenocarcinomas with different types of KRAS mutations show significant differences in their molecular features and clinical manifestations.Given the critical role of KRAS gene mutations in the progression of pancreatic ductal adenocarcinoma,the development of targeted drugs against KRAS mutations has been a research hot spot.This review has comprehensively summarized the molecular features and clinical characteristics of pancreatic ductal adenocarcinomas with different KRAS mutations,discussed in detail the targeted drugs developed against these mutations and their applications in clinical treatment,outlooked the future perspectives of the development of therapeutic strategies.
